Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

75.82 +0.77 (+1.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,339,964
Open 74.62
Bid (Size) 72.56 (100)
Ask (Size) 76.27 (400)
Prev. Close 75.05
Today's Range 73.89 - 76.12
52wk Range 55.64 - 82.26
Shares Outstanding 142,334,900
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
1 Value Stock Worth Investigating and 2 Facing Headwinds
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t... 
Via StockStory
News headline image
2 Reasons to Like HALO and 1 to Stay Skeptical
Halozyme Therapeutics trades at $78.57 and has moved in lockstep with the market. Its shares have returned 8.5% over the last six months while the S&P 500 ha... 
Via StockStory
Topics Stocks

Performance

YTD
+7.8%
+7.8%
1 Month
+6.4%
+6.4%
3 Month
+11.4%
+11.4%
6 Month
+3.9%
+3.9%
1 Year
+34.0%
+34.0%

More News

Read More
News headline image
1 Surging Stock for Long-Term Investors and 2 We Brush Off
Via StockStory
Halozyme Therapeutics (NASDAQ:HALO): A Value Stock Profile Offering Strong Profitability and a Low Forward P/E ↗
Via Chartmill
News headline image
2 Profitable Stocks Worth Your Attention and 1 We Question
Via StockStory
Topics Credit Cards
Halozyme Therapeutics Inc (NASDAQ:HALO): A Deep Value Play Combining Strong Profitability with an Attractive 14.35 P/E ↗
Via Chartmill
Halozyme Therapeutics (NASDAQ:HALO) Surges After Q1 Beat, Launches $1 Billion Buyback ↗
Via Chartmill
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today
Via StockStory
Topics Economy
News headline image
Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions
Via StockStory
Topics Earnings
News headline image
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know
Via StockStory
Topics Economy
News headline image
Therapeutics Stocks Q1 Recap: Benchmarking Halozyme Therapeutics (NASDAQ:HALO)
Via StockStory
Topics Artificial Intelligence
Halozyme Therapeutics Inc (NASDAQ:HALO) Reports Mixed Q4 2025 Results with Revenue Beat and Unexpected Loss ↗
Via Chartmill
News headline image
HALO Q1 Deep Dive: Royalty Expansion and Pipeline Progress Shape 2026 Outlook
Via StockStory
News headline image
Halozyme (HALO) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Halozyme Therapeutics Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Halozyme Therapeutics’s (NASDAQ:HALO) Q1 CY2026 Sales Top Estimates
Via StockStory
News headline image
Halozyme Therapeutics Earnings: What To Look For From HALO
Via StockStory
Topics Artificial Intelligence
News headline image
1 of Wall Street’s Favorite Stock with Exciting Potential and 2 That Underwhelm
Via StockStory
News headline image
3 Cash-Producing Stocks with Exciting Potential
Via StockStory
News headline image
2 Small-Cap Stocks with Solid Fundamentals and 1 We Ignore
Via StockStory
News headline image
1 Small-Cap Stock for Long-Term Investors and 2 We Brush Off
Via StockStory
News headline image
Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
2 Reasons to Like HALO (and 1 Not So Much)
Via StockStory
Topics Stocks
News headline image
Halozyme (HALO) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings

Frequently Asked Questions

Is Halozyme Therapeutics, Inc. - Common Stock publicly traded?
Yes, Halozyme Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Halozyme Therapeutics, Inc. - Common Stock trade on?
Halozyme Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Halozyme Therapeutics, Inc. - Common Stock?
The ticker symbol for Halozyme Therapeutics, Inc. - Common Stock is HALO on the Nasdaq Stock Market
What is the current price of Halozyme Therapeutics, Inc. - Common Stock?
The current price of Halozyme Therapeutics, Inc. - Common Stock is 75.82
When was Halozyme Therapeutics, Inc. - Common Stock last traded?
The last trade of Halozyme Therapeutics, Inc. - Common Stock was at 07/15/26 04:00 PM ET
What is the market capitalization of Halozyme Therapeutics, Inc. - Common Stock?
The market capitalization of Halozyme Therapeutics, Inc. - Common Stock is 10.79B
How many shares of Halozyme Therapeutics, Inc. - Common Stock are outstanding?
Halozyme Therapeutics, Inc. - Common Stock has 11B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS